Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.

Chao TC, Wang WS, Yen CC, Chiou TJ, Liu JH, Chen PM. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. Cancer Invest. 2003; 21(6):837-47.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.